Peptide Initiative

Peptides · Peptide comparison

Polymyxin B vs Thymosin Alpha-1

Cyclic lipopeptide antibiotic from Paenibacillus polymyxa containing 10 amino acids with 6 diaminobutyric acid residues and a fatty acid tail — FDA-approved since 1964 as a last-resort treatment for multidrug-resistant Gram-negative infections including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae, targeting lipid A of bacterial lipopolysaccharide with rapid bactericidal membrane disruption

Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.

  • Immune
  • Immune

At a glance

Quick comparison

Dose rangePolymyxin B1.25–1.5 mg/kgThymosin Alpha-11.6–1.6 mg
FrequencyPolymyxin BMultiple times dailyThymosin Alpha-1Twice weekly
AdministrationPolymyxin BIntravenous infusion (on the FDA label)Thymosin Alpha-1Subcutaneous injection
Cycle lengthPolymyxin B7-14 days, infection-dependent — no source sets a fixed courseThymosin Alpha-18-12 weeks
Onset speedPolymyxin BRapid (hours to days)Thymosin Alpha-1Moderate (1-2 weeks)
Evidence levelPolymyxin BStrong human trials (Phase 3 or FDA approved)Thymosin Alpha-1Moderate human trials (Phase 1-2)

Efficacy

Benefit ratings

Fighting Resistant Infections

Polymyxin B97%
Thymosin Alpha-1No recorded rating

Stopping Bacterial Toxins

Polymyxin B88%
Thymosin Alpha-1No recorded rating

Wound Protection

Polymyxin B82%
Thymosin Alpha-1No recorded rating

Immune Activation

Polymyxin BNo recorded rating
Thymosin Alpha-195%

Infection Fighting

Polymyxin BNo recorded rating
Thymosin Alpha-192%

Immune Balance

Polymyxin BNo recorded rating
Thymosin Alpha-188%

Technical data

Compound specifications

Polymyxin B

Molecular formula
C₅₆H₉₈N₁₆O₁₃ (polymyxin B₁ free base)
Molecular weight
1,203.5 g/mol (free base); ~1,385 g/mol (sulfate salt)
Half-life
Terminal half-life: 9-11.5 hours in patients with normal renal function; does not require renal dose adjustment (unlike colistimethate); achieves steady-state within 1-2 days with loading dose
Bioavailability
IV: 100% (direct administration); oral: negligible (not absorbed from GI tract — used topically in the gut for selective decontamination); inhaled: local pulmonary concentrations achieved with systemic absorption variable; topical: minimal systemic absorption
CAS number
1405-20-5 (polymyxin B sulfate)

Thymosin Alpha-1

Molecular formula
C129H215N33O55
Molecular weight
3108.32 g/mol
Half-life
Approximately 2 hours
Bioavailability
High when injected subcutaneously (rapid absorption, peak at ~2 hours)
CAS number
62304-98-7

Protocols

Dosing compared

Polymyxin B

Intravenous

  • Loading dose 2.0-2.5 mg/kg (20,000-25,000 units/kg)Once on day 1 · Day 1 loading, then maintenanceThe consensus loading dose for serious multidrug-resistant Gram-negative infection, by total body weight, infused over 1 hour [7]. It is not on the FDA label, which predates this guidance [6]. 1 mg of polymyxin B is 10,000 units — a dose quoted without saying which convention it uses cannot be interpreted [7].
  • 1.25-1.5 mg/kg (12,500-15,000 units/kg) per doseEvery 12 hours · 7-14 days, infection-dependentConsensus maintenance dosing, infused over 1 hour [7]. That works out to 2.5-3 mg/kg/day, or 25,000-30,000 units/kg/day — ABOVE the FDA label's stated maximum of 25,000 units/kg/day [6], which is one of the outdated-product-information problems the consensus panel was convened to resolve [7]. Unlike colistin, polymyxin B is not dose-reduced for renal impairment or dialysis [7]; the FDA label, written before that was understood, does instruct reduction in renal impairment [6]. This is a hospital drug given by clinicians who know which convention they are using.

Intramuscular

  • 25,000-30,000 units/kg/day divided every 4-6 hoursEvery 4-6 hours · Infection-dependentFDA label intramuscular dosing; not generally recommended due to injection-site pain. [6]

Intrathecal

  • 50,000 units once daily for 3-4 days, then 50,000 units every other dayDaily then every other day · At least 2 weeks after CSF cultures turn negativeFDA label intrathecal regimen for meningitis (adults and children >2 yr); typically given with concomitant IV polymyxin. Children <2 yr: 20,000 units/day for 3-4 days. [6]

Topical

  • 10,000-25,000 units/mL solution, 1-3 dropsHourly at first, lengthening the interval as the response allows · Until infection resolvesTopical and subconjunctival use for eye infections caused by susceptible Pseudomonas aeruginosa is on the FDA label [6]. The concentration is 0.1-0.25%, which is the same thing as 10,000-25,000 units per mL — written here in units because that is how the rest of this drug's dosing is expressed.

Thymosin Alpha-1

Subcutaneous injection

  • 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
  • 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].

Applications

Best suited for

Polymyxin B

Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed
Polymyxin B is particularly well-suited for individuals focused on treatment of life-threatening multidrug-resistant gram-negative infections when carbapenems and other agents have failed. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia
Polymyxin B is particularly well-suited for individuals focused on salvage therapy for carbapenem-resistant acinetobacter baumannii (crab) bloodstream infections and pneumonia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis
Polymyxin B is particularly well-suited for individuals focused on intrathecal/intraventricular treatment of mdr gram-negative meningitis and ventriculitis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy
Polymyxin B is particularly well-suited for individuals focused on inhaled therapy for mdr gram-negative ventilator-associated pneumonia (vap) as adjunct to systemic therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Thymosin Alpha-1

Chronic Hepatitis B or C Support
Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
Cancer Treatment Support
When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
Age-Related Immune Decline
As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
Severe Infection Recovery
In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.

Safety profile

Side effects

Polymyxin B

Common

  • Nephrotoxicity
  • Infusion-related histamine release
  • Neurotoxicity
  • Skin hyperpigmentation

Uncommon

  • Neuromuscular blockade

Serious

  • Acute kidney injury requiring dialysis

Thymosin Alpha-1

Common

  • Injection site reactions

Uncommon

  • Mild fatigue
  • Flu-like symptoms
  • Mild fever
  • Lymph node awareness

Serious

  • Allergic reaction

Research status

Safety & evidence

Polymyxin B

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved. Indicated for acute infections caused by susceptible Pseudomonas aeruginosa (urinary tract, meninges, bloodstream), and for serious infections caused by H. influenzae, E. coli, Aerobacter aerogenes and Klebsiella pneumoniae when less toxic drugs are ineffective or contraindicated. Carries a BOXED WARNING. Meningeal infections must be treated by the intrathecal route only.
Safety overview
Polymyxin B carries a BOXED WARNING, and it is the most important thing on this page [6]. When given intramuscularly or intrathecally it is to be given only to hospitalised patients under constant physician supervision. Renal function must be determined before use and dosage reduced in renal damage; nephrotoxicity shows as albuminuria, cellular casts and azotemia, and falling urine output with a rising BUN is an instruction to stop the drug. Neurotoxic reactions present as irritability, weakness, drowsiness, ataxia, perioral paraesthesia, numbness of the extremities and blurred vision, usually with the high serum levels seen in renal impairment. Most seriously, the label states the neurotoxicity CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, especially when given soon after anaesthesia or muscle relaxants. The boxed warning names the drugs to avoid concurrently or sequentially: bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin and colistin. Safety in human pregnancy has not been established. Beyond the box, the label reports drug fever, urticarial rash, severe pain at intramuscular injection sites, thrombophlebitis at intravenous sites, and Clostridioides difficile associated diarrhoea ranging from mild to fatal colitis, which can begin more than two months after the antibiotic was given [6].

Contraindications

  • Prior hypersensitivity reaction to polymyxins — the FDA label's only stated contraindication [6]
  • Concurrent or sequential use of other neurotoxic or nephrotoxic drugs, which the boxed warning names: bacitracin, streptomycin, neomycin, kanamycin, gentamicin, tobramycin, amikacin, cephaloridine, paromomycin, viomycin and colistin [6]
  • Soon after anaesthesia or muscle relaxants — the boxed warning flags respiratory paralysis from neuromuscular blockade [6]
  • Pregnancy — the boxed warning states safety in human pregnancy has not been established [6]
  • Myasthenia gravis — neuromuscular blockade is the mechanism behind the label's respiratory-paralysis warning

Thymosin Alpha-1

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
Safety overview
Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.

Contraindications

  • Organ transplant recipients on immunosuppressants
  • Active autoimmune disease flares
  • Known allergy to thymosin peptides
  • Pregnancy or breastfeeding
  • Children under 18 without medical supervision

Decision guide

Which is right for you?

Polymyxin B

Choose Polymyxin B if…

  • Treatment of life-threatening multidrug-resistant Gram-negative infections when carbapenems and other agents have failed
  • Salvage therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) bloodstream infections and pneumonia
  • Intrathecal/intraventricular treatment of MDR Gram-negative meningitis and ventriculitis
  • Inhaled therapy for MDR Gram-negative ventilator-associated pneumonia (VAP) as adjunct to systemic therapy

Thymosin Alpha-1

Choose Thymosin Alpha-1 if…

  • Immune system strengthening
  • Chronic infection support
  • Cancer adjunct therapy
  • Healthy aging immune support